title: Graves' orbitopathy: Management of difficult cases.
abstract: Management of Graves' ophthalmopathy (GO) is based on three pillars: to stop smoking, to restore and maintain euthyroidism, and to treat the eye changes according to severity and activity of GO. Difficulties are frequently encountered in each of these three management issues. The advice to discontinue smoking is straightforward, but just a small minority of smokers is able to quit smoking. Detailed information on how smoking adversely affects the outcome of Graves' disease may convince patients they have to stop smoking right away. Controversy exists on the most appropriate treatment of Graves' hyperthyroidism in the presence of GO. 131I therapy is associated with a risk of about 15% for worsening of GO; a preventive course of steroids is indicated in the presence of risk factors (smoking, biochemically severe hyperthyroidism, high level of TSH receptor antibodies, active GO). Alternatives are thyroidectomy or long-term treatment with antithyroid drugs, which apparently are rather neutral with respect to the course of GO. Mild GO is not always perceived as being mild by the patients themselves. Selenium improves mild GO. Moderate-to-severe GO is preferably treated with intravenous methylprednisolone pulses, but serious side effects and relapsing GO do occur. After steroid failure combination therapy with low-dose oral prednisone with either cyclosporine or retrobulbar irradiation can be effective. Dysthyroid optic neuropathy is best treated with IV pulses, followed by orbital decompression if visual functions do not improve. In resistant cases, rituximab might be considered, although failures of this drug are also described.
authors.affiliation: Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Netherlands.
authors.forename: Wilmar M
authors.initials: WM
authors.lastname: Wiersinga
keywords: Decompression; Graves′ Orbitopathy; hyperthyroidism; immunosuppression; management; smoking; unilateral eye disease
references.citation: J Clin Endocrinol Metab. 2011 Feb;96(2):320-32
references.pmid: 21239515
references.citation: N Engl J Med. 1998 Jan 8;338(2):73-8
references.pmid: 9420337
references.citation: J Clin Endocrinol Metab. 2007 May;92(5):1653-8
references.pmid: 17299076
references.citation: Clin Endocrinol (Oxf). 2010 Jun;72(6):853-5
references.pmid: 20039891
references.citation: J Clin Endocrinol Metab. 2009 Aug;94(8):2708-16
references.pmid: 19491222
references.citation: J Clin Endocrinol Metab. 2012 Nov;97(11):3857-65
references.pmid: 22962421
references.citation: Br J Ophthalmol. 1998 Jul;82(7):773-9
references.pmid: 9924370
references.citation: Br J Ophthalmol. 2003 Jun;87(6):773-6
references.pmid: 12770979
references.citation: J Clin Endocrinol Metab. 2004 Jan;89(1):15-20
references.pmid: 14715820
references.citation: Eur J Intern Med. 2008 Nov;19(7):531-6
references.pmid: 19013383
references.citation: Thyroid. 2011 Mar;21(3):279-83
references.pmid: 21190446
references.citation: J Clin Endocrinol Metab. 2011 Mar;96(3):592-9
references.pmid: 21190983
references.citation: J Endocrinol Invest. 2010 Jun;33(6):409-13
references.pmid: 20101098
references.citation: Eur J Endocrinol. 2001 May;144(5):475-83
references.pmid: 11331213
references.citation: N Engl J Med. 1989 Nov 16;321(20):1353-9
references.pmid: 2519530
references.citation: N Engl J Med. 2011 May 19;364(20):1920-31
references.pmid: 21591944
references.citation: Clin Endocrinol (Oxf). 2005 Sep;63(3):323-8
references.pmid: 16117821
references.citation: J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63
references.pmid: 23038682
references.citation: Eur J Endocrinol. 2008 Mar;158(3):273-85
references.pmid: 18299459